NASDAQ : TNON

Tenon Medical, Inc. — News

$6.05 USD

$1.47 (31.95%)

Volume
397.14K
Average Volume
7.28M
Market Capitalization
$3M
P/E Ratio
-0.13
Dividend Yield
0.00%
Price Target
$2.25
Year High
$60.90
Year Low
$4.38
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.03
Source Headline
Tenon Medical, Inc. Announces 1:35 Reverse Stock Split

LOS GATOS, CA / ACCESS Newswire / August 6, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced a 1-for-35 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split will become effective at 12:01, Eastern Time, on August 10, 2026, prior to the commencement of trading on the Nasdaq Capital Market.

accessnewswire.com - 2026-08-06 08:30:00

Tenon Medical, Inc. Sets Date for Second Quarter 2026 Earnings

LOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON)("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced plans to release financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 13, 2026. The Company will also hold a conference call on the same day at 4:30 p.m.

accessnewswire.com - 2026-07-30 08:00:00

Tenon Medical, Inc. Announces Regained Compliance with Nasdaq Stockholders' Equity Requirement

LOS GATOS, CA / ACCESS Newswire / July 20, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from Nasdaq that the Company regained compliance with the continued listing requirement relating to maintaining a minimum of $2.5 million in stockholders' equity. On July 17, 2026, the Company received a notice from Nasdaq that, based on the July 10 8-K (as defined below), the Company had regained compliance with the Stockholders' Equity Rule (as defined below).

accessnewswire.com - 2026-07-20 08:00:00

Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System

~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~ ~ Clearance reflects Tenon's commitment to continuous innovation and operational efficiency, with reusable instrumentation expected to drive lower capex and logistical spend, contributing positively to gross margins and cash flow ~ LOS GATOS, CA / ACCESS Newswire / July 2, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Catamaran® SI Joint Fusion System. The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status.

accessnewswire.com - 2026-07-02 08:00:00

WallachBeth Capital Announces Closing of Tenon Medical, Inc. $4.2 Million Public Offering

JERSEY CITY, N.J., July 1, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.

prnewswire.com - 2026-07-01 12:45:00

Tenon Medical, Inc. Announces Closing of $4.2 Million Public Offering

LOS GATOS, CA / ACCESS Newswire / July 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company. The offering consisted of 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants.

accessnewswire.com - 2026-07-01 12:10:00

WallachBeth Capital Announces Pricing of Tenon Medical, Inc. $4.2 Million Public Offering

JERSEY CITY, N.J., June 30, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.

prnewswire.com - 2026-06-30 10:00:00

Tenon Medical, Inc. Announces Pricing of $4.2 Million Public Offering

LOS GATOS, CA / ACCESS Newswire / June 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company. The offering consists of up to 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants.

accessnewswire.com - 2026-06-30 09:25:00

Tenon(R) Medical Reports First Quarter 2026 Financial Results

~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~ ~ Gross Margin Expanded Approximately 24 Percentage Points Year-Over-Year to 68.5% ~ ~ Closed $4.3 Million Senior Convertible Note Private Placement to Fund Commercial Expansion and Product Development ~ ~ Subsequent to Quarter End The Company Opened a new Center of Excellence Training Center in Tampa, FL, Along with Expansion of the Company's Sales Leadership Throughout the Eastern Region~ LOS GATOS, CA / ACCESS Newswire / May 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the first quarter ended March 31, 2026. Financial Results and Business Updates First Quarter 2026 Results: First quarter revenue of $1.4 million, an increase of approximately 90% compared to $0.7 million in the first quarter of 2025.

accessnewswire.com - 2026-05-12 16:05:00

Get TNON Insider Trade Alerts

TNON Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$2.25

1 analysts

Last Year

$2.25

1 analysts

All Time

$2.25

1 analysts

TNON Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2024-11-15 Maxim Group Maintain Buy Buy
2024-08-14 Benchmark Maintain Speculative Buy Speculative Buy
2024-04-15 Benchmark Maintain Speculative Buy Speculative Buy